ConductScience.org, home

Paper17538163

Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.

Agulnik M and 18 others. J Clin Oncol, 2007. Cited by 65 papers, by iCite.

Cite this record

ConductScience Library. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. Papers, record 17538163. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538163

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
PubMed
Journal
J Clin Oncol
PubMed
Year
2007
PubMed
Publication types
Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
65
iCite
Relative citation ratio, by iCite
1.43
iCite
Revised in PubMed
2018-12-01
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Agulnik MMark
2da Cunha Santos GGilda
3Hedley DDavid
4Nicklee TTrudey
5Dos Reis PPPatricia Pintor
6Ho JJames
7Pond GRGregory R
8Chen HHeidi
9Chen SShuo
10Shyr YYu
11Winquist EEric
12Soulieres DDenis
13Chen EXEric X
14Squire JAJeremy A
15Marrano PPaula
16Kamel-Reid SSuzanne
17Dancey JJanet
18Siu LLLillian L
19Tsao MSMing S

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Squamous CellMajor topic
ErbB ReceptorsMajor topic
Head and Neck NeoplasmsMajor topic
Protein Kinase InhibitorsMajor topic
QuinazolinesMajor topic
SkinMajor topic
Biomarkers, Tumor
Biopsy
Erlotinib Hydrochloride
Gene Dosage
Humans
Neoplasm Recurrence, Local

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
N01-CO-124001NCI NIH HHSUnited StatesN01CO124001PubMed

Source NIH RePORTER

Download CSV of grants

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00030576Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck CancerResultsClinicalTrials.gov
NCT01195922Rapamycin Therapy in Head and Neck Squamous Cell CarcinomaBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in17538157Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.https://conductscience.org/library/papers/17538157

Source PubMed

Download CSV of comments and corrections

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.

PMIDTitleJournalYearIn PapersSource
33713851RePhine: An Integrative Method for Identification of Drug Response-related Transcriptional Regulators.Genomics Proteomics Bioinformatics2021https://conductscience.org/library/papers/33713851PubMed
29467321Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.JCI Insight2018https://conductscience.org/library/papers/29467321PubMed
29232766Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.Cell Prolif2018https://conductscience.org/library/papers/29232766PubMed
27094362Is there a role of synovial biopsy in drug development?BMC Musculoskelet Disord2016https://conductscience.org/library/papers/27094362PubMed
26120042In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas.Sci Rep2015https://conductscience.org/library/papers/26120042PubMed
25702049Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.Cancer Chemother Pharmacol2015https://conductscience.org/library/papers/25702049PubMed
25482928
Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
Cancer Biol Ther2015https://conductscience.org/library/papers/25482928PubMed
23342298Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.Am J Nucl Med Mol Imaging2013https://conductscience.org/library/papers/23342298PubMed
22907806Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.Head Neck2013https://conductscience.org/library/papers/22907806PubMed
22785204Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.Cancer Biol Ther2012https://conductscience.org/library/papers/22785204PubMed
22732263Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.Oral Oncol2012https://conductscience.org/library/papers/22732263PubMed
21829197Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.Br J Cancer2011https://conductscience.org/library/papers/21829197PubMed
21352589The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.Head Neck Oncol2011https://conductscience.org/library/papers/21352589PubMed
21274259Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study.J Oncol2010https://conductscience.org/library/papers/21274259PubMed
21188133Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer.Cancer Manag Res2009https://conductscience.org/library/papers/21188133PubMed
21048039
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Ann Oncol2011https://conductscience.org/library/papers/21048039PubMed
20832752In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.Cancer Cell2010https://conductscience.org/library/papers/20832752PubMed
20570883Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.Cancer Prev Res (Phila)2010https://conductscience.org/library/papers/20570883PubMed
20197396Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.Mol Cancer Ther2010https://conductscience.org/library/papers/20197396PubMed
20009104EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.Sci Signal2009https://conductscience.org/library/papers/20009104PubMed

See all 30 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
DCTN610671PubTator's text mininghttps://conductscience.org/library/genes/10671NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
NFKB14790PubTator's text mininghttps://conductscience.org/library/genes/4790NCBI Gene
STAT36774PubTator's text mininghttps://conductscience.org/library/genes/6774NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CISPLATINCHEMBL11359Results1https://conductscience.org/library/drugs/CHEMBL11359ChEMBL
ERLOTINIBCHEMBL553Results1https://conductscience.org/library/drugs/CHEMBL553ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17538163

GET https://conductscience.org/api/papers/v1/17538163/cited_by?page=2